Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 1;12(1):e2020008.
doi: 10.4084/MJHID.2020.008. eCollection 2020.

Cardiovascular Risk in Essential Thrombocythemia and Polycythemia Vera: Thrombotic Risk and Survival

Vincenzo Accurso  1 , Marco Santoro  2 , Salvatrice Mancuso  1 , Angelo Davide Contrino  1 , Paolo Casimiro  1 , Mariano Sardo  1 , Simona Raso  2 , Florinda Di Piazza  3 , Alessandro Perez  3 , Marco Bono  3 , Antonio Russo  3 , Sergio Siragusa  1
Affiliations

Cardiovascular Risk in Essential Thrombocythemia and Polycythemia Vera: Thrombotic Risk and Survival

Vincenzo Accurso et al. Mediterr J Hematol Infect Dis. .

Abstract

Thromboembolic and bleeding events pose a severe risk for patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Many factors can contribute to promoting the thrombotic event due to the interaction between platelets, leukocytes, and endothelium alterations. Moreover, a significant role can be played by cardiovascular risk factors (CV.R) such as cigarette smoking habits, hypertension, diabetes, obesity and dyslipidemia. In this study, we evaluated the impact that CV.R plays on thrombotic risk and survival in patients with PV and ET.

Keywords: Essential Thrombocythemia; Polycythemia Vera.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no conflict of Interest.

Figures

Figure 1
Figure 1
Survival and CVR factors in PV (A) and ET (B) patients.
See this image and copyright information in PMC

References

    1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405. doi: 10.1182/blood-2016-03-643544. - DOI - PubMed
    1. Tefferi A, Barbui T. Polycytemia vera and essential thrombocythemia:2019 update on diagnosis risk stratification and management. Am J Hematol. 2019 Jan;94(1):133–143. doi: 10.1002/ajh.25303. - DOI - PubMed
    1. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507–2513. doi: 10.1182/blood-2014-05-579136. - DOI - PMC - PubMed
    1. Haider Mahnur, Gangat Naseema, Lasho Terra, Abou Hussein Ahmed K, Elala Yoseph C, Hanson Curtis, Tefferi Ayalew. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. American Journal of Hematology. 2016 Apr;91(4) doi: 10.1002/ajh.24293. - DOI - PubMed
    1. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122:2176–2284. doi: 10.1182/blood-2013-03-460154. - DOI - PubMed